出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2022年11月
HPV検査とパップテスト市場 : 検査の種類 ［HPV 検査 (フォローアップ HPV 検査、共同検査、一次 HPV 検査)、PAP 検査］、エンドユーザー (研究所、病院、診療所、クリニック)、地域別 – 2027 年までの世界予測
HPV Testing and Pap Test Market by Test Type (HPV Testing (Follow-Up HPV Testing, Co- Testing, Primary HPV Testing), PAP Test), End User (Laboratories, Hospitals, Physician’s Offices & Clinics), Region – Global Forecast to 2027
| ページ数 | 181 |
| 図表数 | 246 |
| 種別 | 英文調査報告書 |
| 価格 |
The global HPV testing and Pap test market is projected to reach USD 9.2 billion by 2027 from USD 4.9 billion in 2022, at a CAGR of 13.2% during the forecast period. Market growth is driven by factors such as increased production HPV diagnostic products and government initiatives. On the other hand, challenges associated with HPV testing and Pap test is uncertain reimbursement scenarios is the major factors hampering the growth of this market.
“The HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market, by test type, during the forecast period”
The HPV testing and Pap test market is segmented into HPV testing and Pap test. In 2021, HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market. Increase in number of product approval and increased focus on reducing cancer cases are major factor contributing to the growth of this segment.
“The cervical cancer screening segment accounted for the highest growth rate in the HPV testing and Pap test market, by application, during the forecast period”
The HPV testing and Pap test market is segmented into cervical cancer screening and vaginal cancer screening. In 2021, HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market. Increasing funding for the prevention of cervical cancer are major factor contributing to the growth of this segment.
“The hospitals segment accounted for the highest growth rate in the HPV testing and Pap test market, by end user, during the forecast period”
The HPV testing and Pap test market is segmented into laboratories, hospitals and physician’s offices & clinics based on end user. In 2021, the hospitals segment accounted for the highest growth rate in the HPV testing and Pap test market. Emerging markets offer lucrative growth opportunities are major factors contributing to the growth of this segment.
“Asia Pacific: The fastest-growing region in HPV testing and Pap test market”
The global HPV testing and Pap test market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Increasing number of conferences focused on creating awareness of cervical cancer is driving the growth of the HPV testing and Pap test market in this region.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
• By Designation: C-level – 27%, D-level – 18%, and Others – 55%
• By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and the Middle East & Africa – 4%
Lists of Companies Profiled in the Report:
• Abbott Laboratories (US)
• Roche Diagnostics (Switzerland)
• Becton, Dickinson and Company (US)
• Hologic, Inc. (US)
• Quest Diagnostics (US)
• Qiagen N.V. (Netherland)
• Seegene, Inc. (US)
• Femasys, Inc. (US)
• Arbor Vita Corporation (US)
• Mylab Discovery Solutions Pvt. Ltd. (India)
• EverlyWell, Inc. (US)
• Nurx, Inc. (US)
• Dalrada Corporation (US)
• NeoDiagnostix (US)
• Jiangsu Mole Bioscience Co., Ltd. (China)
• Sansure Biotech Inc. (China)
Research Coverage:
This report provides a detailed picture of the global HPV testing and Pap test market. It aims at estimating the size and future growth potential of the market across different segments, such as test type, application, end user and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall HPV testing and Pap test market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities and challenges.
目次
1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.2.1 INCLUSIONS AND EXCLUSIONS 31
1.3 MARKETS COVERED 31
FIGURE 1 HPV TESTING AND PAP TEST MARKET SEGMENTATION 31
1.3.1 YEARS CONSIDERED 32
1.4 CURRENCY CONSIDERED 32
1.5 LIMITATIONS 32
1.6 STAKEHOLDERS 33
1.7 SUMMARY OF CHANGES 33
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
2.2 RESEARCH APPROACH 34
FIGURE 2 HPV TESTING AND PAP TEST MARKET: RESEARCH DESIGN 34
2.2.1 SECONDARY DATA 35
2.2.1.1 Key data from secondary sources 35
2.2.2 PRIMARY DATA 36
2.2.2.1 Primary sources 37
2.2.2.2 Key data from primary sources 37
2.2.2.3 Key industry insights 38
2.2.2.4 Breakdown of primary interviews 38
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 38
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 39
2.3 MARKET SIZE ESTIMATION 39
2.3.1 BOTTOM-UP APPROACH 40
2.3.1.1 Approach 1: Company revenue estimation approach 40
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 40
2.3.1.2 Approach 2: Presentations of companies and primary interviews 40
2.3.1.3 CAGR projections 41
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 41
2.3.2 TOP-DOWN APPROACH 41
FIGURE 7 HPV TESTING AND PAP TEST MARKET: TOP-DOWN APPROACH 41
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 42
FIGURE 8 DATA TRIANGULATION METHODOLOGY 42
2.5 MARKET SHARE ANALYSIS 43
2.6 STUDY ASSUMPTIONS 43
2.7 GROWTH RATE ASSUMPTIONS 43
2.8 RISK ASSESSMENT 44
2.8.1 HPV TESTING AND PAP TEST MARKET: RISK ASSESSMENT 44
3 EXECUTIVE SUMMARY 45
FIGURE 9 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2022 VS. 2027 (USD MILLION) 45
FIGURE 10 HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 46
FIGURE 11 HPV TESTING AND PAP TEST MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 46
FIGURE 12 HPV TESTING AND PAP TEST MARKET, BY REGION, 2022 VS. 2027 (USD MILLION) 47
4 PREMIUM INSIGHTS 48
4.1 HPV TESTING AND PAP TEST MARKET OVERVIEW 48
FIGURE 13 RISING CASES OF HPV AND INCREASING R&D INITIATIVES ON CERVICAL CANCER SCREENING TO DRIVE MARKET 48
4.2 HPV TESTING AND PAP TEST MARKET SHARE, BY TEST TYPE, 2022 VS. 2027 49
FIGURE 14 HPV TESTING SEGMENT TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD 49
4.3 HPV TESTING AND PAP TEST MARKET SHARE, BY APPLICATION, 2022 VS. 2027 49
FIGURE 15 CERVICAL CANCER SCREENING SEGMENT TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD 49
4.4 HPV TESTING AND PAP TEST MARKET SHARE, BY END USER, 2022 VS. 2027 50
FIGURE 16 HOSPITALS TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 50
4.5 HPV TESTING AND PAP TEST MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 50
FIGURE 17 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 50
5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
FIGURE 18 HPV TESTING AND PAP TEST MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51
5.2.1 DRIVERS 52
5.2.1.1 Rising HPV cases and subsequent increase in cervical cancer 52
5.2.1.2 Growing awareness of cervical cancer screening programs 52
5.2.1.3 Increasing R&D funding initiatives on cervical cancer prevention 53
5.2.2 RESTRAINTS 54
5.2.2.1 Growing awareness of HPV vaccination 54
5.2.3 OPPORTUNITIES 54
5.2.3.1 Regulatory guidelines for cervical cancer screening 54
5.2.3.2 Innovative improvements in HPV tests 54
5.2.3.2.1 Introduction of HPV primary screening tests 55
5.2.3.2.2 Technological improvements in HPV tests 55
5.2.4 CHALLENGES 56
5.2.4.1 Uncertain reimbursement scenario 56
5.2.4.2 Stringent regulatory & legal requirements 56
5.2.4.3 Operational barriers 57
5.3 PRICING ANALYSIS 57
TABLE 1 PRICE OF HPV TESTING AND PAP TEST PRODUCTS (2021) 57
5.4 PATENT ANALYSIS 58
FIGURE 19 PATENT ANALYSIS OF HPV TESTING AND PAP TEST MARKET 58
5.5 VALUE CHAIN ANALYSIS 59
FIGURE 20 VALUE CHAIN ANALYSIS OF HPV TESTING AND PAP TEST MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 59
5.6 SUPPLY CHAIN ANALYSIS 60
FIGURE 21 HPV TESTING AND PAP TEST MARKET: SUPPLY CHAIN ANALYSIS 60
5.7 ECOSYSTEM/MARKET MAP 61
FIGURE 22 HPV TESTING AND PAP TEST MARKET: ECOSYSTEM/MARKET MAP 61
5.7.1 HPV TESTING AND PAP TEST MARKET: ROLE IN ECOSYSTEM 61
5.8 PORTER’S FIVE FORCES ANALYSIS 62
TABLE 2 HPV TESTING AND PAP TEST MARKET: PORTER’S FIVE FORCES ANALYSIS 62
5.8.1 THREAT OF NEW ENTRANTS 62
5.8.2 THREAT OF SUBSTITUTES 62
5.8.3 BARGAINING POWER OF BUYERS 62
5.8.4 BARGAINING POWER OF SUPPLIERS 63
5.8.5 DEGREE OF COMPETITION 63
5.9 TRADE ANALYSIS 63
5.9.1 TRADE ANALYSIS FOR DIAGNOSTIC OR LABORATORY REAGENTS 63
TABLE 3 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION) 63
TABLE 4 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION) 63
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 64
5.10.1 REVENUE SOURCES SHIFTING TOWARD TECHNOLOGY-BASED SOLUTIONS DUE TO COVID-19 64
FIGURE 23 REVENUE SHIFT IN HPV TESTING AND PAP TEST MARKET 64
6 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE 65
6.1 INTRODUCTION 66
TABLE 5 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION) 66
TABLE 6 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION) 66
TABLE 7 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS) 67
TABLE 8 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS) 67
6.2 HPV TESTING 67
TABLE 9 HPV TESTING MARKET, BY TEST TYPE, 2017–2020 (USD MILLION) 68
TABLE 10 HPV TESTING MARKET, BY TEST TYPE, 2021–2027 (USD MILLION) 68
TABLE 11 HPV TESTING MARKET, BY REGION, 2017–2020 (USD MILLION) 68
TABLE 12 HPV TESTING MARKET, BY REGION, 2021–2027 (USD MILLION) 69
6.2.1 FOLLOW-UP HPV TESTING 69
6.2.1.1 Irregular Pap test results to drive adoption 69
TABLE 13 FOLLOW-UP HPV TESTING MARKET, BY REGION, 2017–2020 (USD MILLION) 69
TABLE 14 FOLLOW-UP HPV TESTING MARKET, BY REGION, 2021–2027 (USD MILLION) 70
6.2.2 CO-TESTING 70
6.2.2.1 Co-testing to drive rapid detection results for cervical cancer 70
TABLE 15 HPV CO-TESTING MARKET, BY REGION, 2017–2020 (USD MILLION) 70
TABLE 16 HPV CO-TESTING MARKET, BY REGION, 2021–2027 (USD MILLION) 71
6.2.3 PRIMARY HPV TESTING 71
6.2.3.1 Test sensitivity and accuracy to drive segment growth 71
TABLE 17 PRIMARY HPV TESTING MARKET, BY REGION, 2017–2020 (USD MILLION) 71
TABLE 18 PRIMARY HPV TESTING MARKET, BY REGION, 2021–2027 (USD MILLION) 72
6.3 PAP TEST 72
6.3.1 RISING CASES OF FALSE-NEGATIVE TESTS TO RESTRAIN MARKET 72
TABLE 19 PAP TEST MARKET, BY REGION, 2017–2020 (USD MILLION) 72
TABLE 20 PAP TEST MARKET, BY REGION, 2021–2027 (USD MILLION) 73
7 HPV TESTING AND PAP TEST MARKET, BY APPLICATION 74
7.1 INTRODUCTION 75
TABLE 21 HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 75
TABLE 22 HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 75
7.2 CERVICAL CANCER SCREENING 75
7.2.1 RISING INCIDENCE OF CERVICAL CANCER TO DRIVE MARKET 75
TABLE 23 HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY REGION, 2017–2020 (USD MILLION) 76
TABLE 24 HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY REGION, 2021–2027 (USD MILLION) 76
7.3 VAGINAL CANCER SCREENING 77
7.3.1 LIMITED SCREENING TESTS TO RESTRAIN MARKET 77
TABLE 25 HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY REGION, 2017–2020 (USD MILLION) 77
TABLE 26 HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY REGION, 2021–2027 (USD MILLION) 77
8 HPV TESTING AND PAP TEST MARKET, BY END USER 78
8.1 INTRODUCTION 79
TABLE 27 HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION) 79
TABLE 28 HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION) 79
8.2 HOSPITALS 79
8.2.1 ADVANCED TECHNOLOGIES AND EQUIPPED FACILITIES TO DRIVE MARKET 79
TABLE 29 HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY REGION, 2017–2020 (USD MILLION) 80
TABLE 30 HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY REGION, 2021–2027 (USD MILLION) 80
8.3 LABORATORIES 81
8.3.1 INCREASING OUTSOURCING OF DIAGNOSTIC TESTS TO LABORATORIES TO DRIVE MARKET 81
TABLE 31 HPV TESTING AND PAP TEST MARKET FOR LABORATORIES, BY REGION, 2017–2020 (USD MILLION) 81
TABLE 32 HPV TESTING AND PAP TEST MARKET FOR LABORATORIES, BY REGION, 2021–2027 (USD MILLION) 82
8.4 PHYSICIANS’ OFFICES AND CLINICS 82
8.4.1 RAPID AND EFFICIENT RESULTS TO SUPPORT MARKET GROWTH 82
TABLE 33 HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS’ OFFICES AND CLINICS, BY REGION, 2017–2020 (USD MILLION) 82
TABLE 34 HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS’ OFFICES AND CLINICS, BY REGION, 2021–2027 (USD MILLION) 83
9 HPV TESTING AND PAP TEST MARKET, BY REGION 84
9.1 INTRODUCTION 85
TABLE 35 HPV TESTING AND PAP TEST MARKET, BY REGION, 2017–2020 (USD MILLION) 85
TABLE 36 HPV TESTING AND PAP TEST MARKET, BY REGION, 2021–2027 (USD MILLION) 85
9.2 NORTH AMERICA 86
FIGURE 24 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET SNAPSHOT 87
TABLE 37 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2017–2020 (USD MILLION) 87
TABLE 38 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2021–2027 (USD MILLION) 88
TABLE 39 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION) 88
TABLE 40 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION) 88
TABLE 41 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS) 89
TABLE 42 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS) 89
TABLE 43 NORTH AMERICA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION) 89
TABLE 44 NORTH AMERICA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION) 90
TABLE 45 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 90
TABLE 46 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 90
TABLE 47 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION) 91
TABLE 48 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION) 91
9.2.1 US 91
9.2.1.1 Rising government initiatives for cancer research to drive market 91
TABLE 49 US: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION) 92
TABLE 50 US: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION) 92
TABLE 51 US: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS) 92
TABLE 52 US: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS) 93
TABLE 53 US: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION) 93
TABLE 54 US: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION) 93
TABLE 55 US: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 94
TABLE 56 US: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 94
TABLE 57 US: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION) 94
TABLE 58 US: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION) 95
9.2.2 CANADA 95
9.2.2.1 Government support in raising awareness on cervical cancer screening to support market growth 95
TABLE 59 CANADA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION) 95
TABLE 60 CANADA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION) 96
TABLE 61 CANADA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION) 96
TABLE 62 CANADA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION) 96
TABLE 63 CANADA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 97
TABLE 64 CANADA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 97
TABLE 65 CANADA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION) 97
TABLE 66 CANADA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION) 98
9.3 EUROPE 98
TABLE 67 EUROPE: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2017–2020 (USD MILLION) 99
TABLE 68 EUROPE: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2021–2027 (USD MILLION) 99
TABLE 69 EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION) 99
TABLE 70 EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION) 100
TABLE 71 EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS) 100
TABLE 72 EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS) 100
TABLE 73 EUROPE: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION) 101
TABLE 74 EUROPE: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION) 101
TABLE 75 EUROPE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 101
TABLE 76 EUROPE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 102
TABLE 77 EUROPE: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION) 102
TABLE 78 EUROPE: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION) 102
9.3.1 GERMANY 103
9.3.1.1 Established healthcare infrastructure and rising government spending on cancer screening to drive market 103
TABLE 79 GERMANY: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION) 103
TABLE 80 GERMANY: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION) 104
TABLE 81 GERMANY: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION) 104
TABLE 82 GERMANY: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION) 104
TABLE 83 GERMANY: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 105
TABLE 84 GERMANY: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 105
TABLE 85 GERMANY: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION) 105
TABLE 86 GERMANY: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION) 106
9.3.2 UK 106
9.3.2.1 Rising focus on research projects for specific cancers to drive market 106
TABLE 87 UK: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION) 107
TABLE 88 UK: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION) 107
TABLE 89 UK: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION) 107
TABLE 90 UK: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION) 108
TABLE 91 UK: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 108
TABLE 92 UK: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 108
TABLE 93 UK: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION) 109
TABLE 94 UK: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION) 109
9.3.3 FRANCE 109
9.3.3.1 High incidence of cervical cancer and associated investments in genomics to support market growth 109
TABLE 95 FRANCE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION) 110
TABLE 96 FRANCE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION) 110
TABLE 97 FRANCE: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION) 110
TABLE 98 FRANCE: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION) 111
TABLE 99 FRANCE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 111
TABLE 100 FRANCE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 111
TABLE 101 FRANCE: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION) 112
TABLE 102 FRANCE: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION) 112
9.3.4 SPAIN 112
9.3.4.1 Increasing research on cancer diagnostics to support market growth 112
TABLE 103 SPAIN: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION) 113
TABLE 104 SPAIN: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION) 113
TABLE 105 SPAIN: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION) 113
TABLE 106 SPAIN: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION) 114
TABLE 107 SPAIN: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 114
TABLE 108 SPAIN: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 114
TABLE 109 SPAIN: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION) 115
TABLE 110 SPAIN: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION) 115
9.3.5 ITALY 115
9.3.5.1 Growing acceptance of molecular-based diagnostic tests for cervical cancer screening to drive market 115
TABLE 111 ITALY: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION) 116
TABLE 112 ITALY: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION) 116
TABLE 113 ITALY: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION) 116
TABLE 114 ITALY: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION) 117
TABLE 115 ITALY: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 117
TABLE 116 ITALY: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 117
TABLE 117 ITALY: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION) 118
TABLE 118 ITALY: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION) 118
9.3.6 REST OF EUROPE 118
TABLE 119 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION) 119
TABLE 120 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION) 119
TABLE 121 REST OF EUROPE: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION) 119
TABLE 122 REST OF EUROPE: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION) 120
TABLE 123 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 120
TABLE 124 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 120
TABLE 125 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION) 121
TABLE 126 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION) 121
9.4 ASIA PACIFIC 122
FIGURE 25 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET SNAPSHOT 123
TABLE 127 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2017–2020 (USD MILLION) 124
TABLE 128 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2021–2027 (USD MILLION) 124
TABLE 129 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION) 124
TABLE 130 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION) 125
TABLE 131 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS) 125
TABLE 132 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS) 125
TABLE 133 ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION) 126
TABLE 134 ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION) 126
TABLE 135 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 126
TABLE 136 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 127
TABLE 137 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION) 127
TABLE 138 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION) 127
9.4.1 CHINA 128
9.4.1.1 Government initiatives for cancer diagnosis and immunotherapy to support market growth 128
TABLE 139 CHINA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION) 128
TABLE 140 CHINA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION) 128
TABLE 141 CHINA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION) 129
TABLE 142 CHINA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION) 129
TABLE 143 CHINA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 129
TABLE 144 CHINA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 130
TABLE 145 CHINA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION) 130
TABLE 146 CHINA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION) 130
9.4.2 JAPAN 131
9.4.2.1 Rising demand for technologically advanced cervical cancer screening tests to drive market 131
TABLE 147 JAPAN: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION) 131
TABLE 148 JAPAN: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION) 131
TABLE 149 JAPAN: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION) 132
TABLE 150 JAPAN: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION) 132
TABLE 151 JAPAN: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 132
TABLE 152 JAPAN: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 133
TABLE 153 JAPAN: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION) 133
TABLE 154 JAPAN: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION) 133
9.4.3 INDIA 134
9.4.3.1 High cancer burden and rising pharmaceutical industry to drive market 134
TABLE 155 INDIA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION) 134
TABLE 156 INDIA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION) 134
TABLE 157 INDIA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION) 135
TABLE 158 INDIA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION) 135
TABLE 159 INDIA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 135
TABLE 160 INDIA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 136
TABLE 161 INDIA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION) 136
TABLE 162 INDIA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION) 136
9.4.4 REST OF ASIA PACIFIC 137
TABLE 163 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION) 137
TABLE 164 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION) 137
TABLE 165 REST OF ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION) 138
TABLE 166 REST OF ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION) 138
TABLE 167 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 138
TABLE 168 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 139
TABLE 169 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION) 139
TABLE 170 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION) 139
9.5 LATIN AMERICA 140
9.5.1 RISING AWARENESS OF ADVANCED CANCER SCREENING TECHNOLOGIES TO DRIVE MARKET 140
TABLE 171 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION) 140
TABLE 172 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION) 140
TABLE 173 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS) 141
TABLE 174 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS) 141
TABLE 175 LATIN AMERICA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION) 141
TABLE 176 LATIN AMERICA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION) 142
TABLE 177 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 142
TABLE 178 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 142
TABLE 179 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION) 143
TABLE 180 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION) 143
9.6 MIDDLE EAST AND AFRICA 143
9.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE DUE TO HIGH CANCER BURDEN TO SUPPORT MARKET GROWTH 143
TABLE 181 MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION) 144
TABLE 182 MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION) 144
TABLE 183 MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS) 144
TABLE 184 MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS) 145
TABLE 185 MIDDLE EAST AND AFRICA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION) 145
TABLE 186 MIDDLE EAST AND AFRICA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION) 145
TABLE 187 MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION) 146
TABLE 188 MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 146
TABLE 189 MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION) 146
TABLE 190 MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION) 147
10 COMPETITIVE LANDSCAPE 148
10.1 OVERVIEW 148
10.2 STRATEGIES ADOPTED BY KEY PLAYERS 148
10.2.1 HPV TESTING AND PAP TEST MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 149
TABLE 191 OVERVIEW OF STRATEGIES ADOPTED BY KEY HPV TESTING AND PAP TEST PLAYERS 149
10.3 REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS 150
FIGURE 26 REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS 150
10.4 MARKET SHARE ANALYSIS 151
FIGURE 27 HPV TESTING AND PAP TEST MARKET SHARE, BY KEY PLAYER (2021) 151
TABLE 192 HPV TESTING AND PAP TEST MARKET: DEGREE OF COMPETITION 151
10.5 COMPANY EVALUATION QUADRANT 152
10.5.1 LIST OF EVALUATED VENDORS 152
10.5.2 STARS 152
10.5.3 EMERGING LEADERS 152
10.5.4 PERVASIVE PLAYERS 152
10.5.5 PARTICIPANTS 153
FIGURE 28 HPV TESTING AND PAP TEST MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021 153
10.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2021) 154
10.6.1 PROGRESSIVE COMPANIES 154
10.6.2 STARTING BLOCKS 154
10.6.3 RESPONSIVE COMPANIES 154
10.6.4 DYNAMIC COMPANIES 154
FIGURE 29 HPV TESTING AND PAP TEST MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2021 155
10.7 COMPETITIVE SCENARIO 156
10.7.1 PRODUCT LAUNCHES & APPROVALS 156
TABLE 193 PRODUCT LAUNCHES & APPROVALS (2020-2022) 156
10.7.2 DEALS 157
TABLE 194 DEALS (2021-2022) 157
10.7.3 OTHER DEVELOPMENTS 157
TABLE 195 OTHER DEVELOPMENTS 157
11 COMPANY PROFILES 158
11.1 KEY PLAYERS 158
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
11.1.1 ABBOTT LABORATORIES 158
TABLE 196 ABBOTT LABORATORIES: BUSINESS OVERVIEW 158
FIGURE 30 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021) 159
11.1.2 ROCHE DIAGNOSTICS 161
TABLE 197 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW 161
FIGURE 31 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2021) 162
11.1.3 HOLOGIC, INC. 165
TABLE 198 HOLOGIC, INC.: BUSINESS OVERVIEW 165
FIGURE 32 HOLOGIC, INC: COMPANY SNAPSHOT (2021) 166
11.1.4 BECTON, DICKINSON AND COMPANY 168
TABLE 199 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 168
FIGURE 33 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021) 169
11.1.5 QUEST DIAGNOSTICS 172
TABLE 200 QUEST DIAGNOSTICS: BUSINESS OVERVIEW 172
FIGURE 34 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2021) 172
11.1.6 QIAGEN N.V. 174
TABLE 201 QIAGEN N.V.: BUSINESS OVERVIEW 174
FIGURE 35 QIAGEN N.V.: COMPANY SNAPSHOT (2021) 175
11.1.7 SEEGENE, INC. 176
TABLE 202 SEEGENE, INC: BUSINESS OVERVIEW 176
11.1.8 FEMASYS, INC. 177
TABLE 203 FEMASYS, INC.: BUSINESS OVERVIEW 177
11.1.9 ARBOR VITA CORPORATION 178
TABLE 204 ARBOR VITA CORPORATION: BUSINESS OVERVIEW 178
11.1.10 MYLAB DISCOVERY SOLUTIONS PVT. LTD. 179
TABLE 205 MYLAB DISCOVERY SOLUTIONS PVT. LTD.: BUSINESS OVERVIEW 179
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
11.2 OTHER PLAYERS 180
11.2.1 EVERLYWELL INC. 180
TABLE 206 EVERLYWELL INC.: COMPANY OVERVIEW 180
11.2.2 NURX INC. 180
TABLE 207 NURX INC.: COMPANY OVERVIEW 180
11.2.3 DALRADA CORPORATION 181
TABLE 208 DALRADA CORPORATION: COMPANY OVERVIEW 181
11.2.4 NEODIAGNOSTIX 181
TABLE 209 NEODIAGNOSTIX: COMPANY OVERVIEW 181
11.2.5 JIANGSU MOLE BIOSCIENCE CO., LTD. 182
TABLE 210 JIANGSU MOLE BIOSCIENCE CO., LTD.: COMPANY OVERVIEW 182
11.2.6 SANSURE BIOTECH INC. 182
TABLE 211 SANSURE BIOTECH, INC.: COMPANY OVERVIEW 182
12 APPENDIX 183
12.1 DISCUSSION GUIDE 183
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 186
12.3 CUSTOMIZATION OPTIONS 188
12.4 RELATED REPORTS 188
12.5 AUTHOR DETAILS 189